Search / Trial NCT06235853

Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer

Launched by WROCLAW MEDICAL UNIVERSITY · Jan 29, 2024

Trial Information

Current as of October 07, 2024

Completed

Keywords

Non Muscle Invasive Bladder Cancer Cystoscopy Recurrence Progression Bladder Cancer Biomarkers

Description

The aim of our prospective study was to determine the prognostic impact of the inflammatory response and indicators of nutritional status on recurrence and progression of non-muscle invasive bladder cancer (NMIBC) in patients undergoing transurethral resection of bladder tumour (TURBT). We evaluated six biomarkers, 3 in blood serum: soluble urokinase plasminogen activator receptor (sUPAR), plasminogen activator inhibitor-1 (PAI-1), interleukin 8 (IL-8) and 3 in urine: apolipoprotein E (APOE), vascular endothelial growth factor (VEGF), interleukin 8 (IL-8). Furthermore, following indicators ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Signed informed consent form
  • * Presence or suspicion of tumour in urinary bladder
  • * Qualification for the first transurethral resection of bladder tumour
  • Exclusion Criteria:
  • 1. age \< 18 years
  • 2. active urinary tract infection
  • 3. active autoimmune disease
  • 4. end-stage renal failure and renal replacement therapy
  • 5. active hepatitis A, B or C
  • 6. active HIV infection
  • 7. pregnancy
  • 8. factors disqualifying the patient from adjuvant treatment (intravesical immunotherapy or intravesical chemotherapy)
  • 9. bladder tumour stage T2 or more, or urothelial tumour in a location other than the urinary bladder
  • 10. other cancer or systemic anticancer treatment carried out up to 5 years ago
  • 11. factors disqualifying the patient from surgical treatment, e.g. coagulopathies
  • 12. lack of patient consent to collection of blood and urine samples and to follow-up visits

About Wroclaw Medical University

Wrocław Medical University is a prestigious academic institution located in Wrocław, Poland, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive expertise in healthcare and biomedical sciences to facilitate innovative research initiatives aimed at improving patient outcomes. With a strong emphasis on ethical practices and regulatory compliance, Wrocław Medical University collaborates with a diverse network of healthcare professionals and researchers to conduct rigorous clinical trials that contribute to the development of new therapies and enhance the understanding of various medical conditions. Its dedication to scientific excellence and patient safety positions the university as a key player in the global clinical research landscape.

Locations

Wrocław, , Poland

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0